ArticleCancer cell2018
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04622423 (Advanced Immune Gene and Cell Therapies for Liver Metastases), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Advanced Immune Gene and Cell Therapies for Liver Metastases
Who cites it
8 citing papers in PubMed, 30 citations in OpenAlex.
- Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma.Cell discovery · 2026Article
- Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity.Heliyon · 2023Article
- Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma.Heliyon · 2020Article
- Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.The oncologist · 2019Article
- Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas.International journal of molecular sciences · 2019Article
- Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer.Cancer communications (London, England) · 2019Review
- PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.The Journal of clinical investigation · 2019Article
- Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.Translational lung cancer research · 2018Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.